Vaillant Andrew
Replicor Inc., 4100 Royalmount Avenue, Montreal, QC H4P 2R2, Canada.
Mol Ther Nucleic Acids. 2022 Mar 23;28:168-174. doi: 10.1016/j.omtn.2022.03.002. eCollection 2022 Jun 14.
The LNA-modified NAP ALG-10133 is inactive against HBV infection in humans compared with the potent activity of non-LNA-modified NAPs such as REP 2139. This inactivity illustrates the negative impact LNA has on the antiviral activity of NAPs and highlights critical artifacts in transfection-based systems used for their evaluation.
与非锁核酸(LNA)修饰的核苷酸类似物(NAP)如REP 2139的强效活性相比,LNA修饰的NAP ALG - 10133对人类乙肝病毒(HBV)感染无活性。这种无活性说明了LNA对NAP抗病毒活性的负面影响,并突出了用于评估它们的基于转染的系统中的关键假象。